12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept
Ziv-aflibercept demonstrated effectiveness in maintaining treatment outcomes in nAMD eyes previously treated with aflibercept. The treatment was well-tolerated with no reported adverse events. Ziv-aflibercept may be a cost-effective alternative and a potential solution to the financial burden associated with conventional anti-VEGF agents.
Authors
- Wajiha Jurdi Kheir (ORCID: https://orcid.org/0000-0002-4063-3860)
- Rola N. Hamam (ORCID: https://orcid.org/0000-0001-8044-4215)
- Ziad F. Bashshur (ORCID: https://orcid.org/0000-0002-7133-5073)
- Mahdi M. Hassoun (ORCID: https://orcid.org/0009-0008-6616-5031)
Institutions
- American University of Beirut (LB)
Publication Details
- Journal
- Indian Journal of Ophthalmology
- Published
- 2024-12-24
- DOI
- https://doi.org/10.4103/ijo.ijo_627_24
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00